1. Home
  2. VRCA vs RGS Comparison

VRCA vs RGS Comparison

Compare VRCA & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

N/A

Current Price

$3.55

Market Cap

88.0M

Sector

Health Care

ML Signal

N/A

Logo Regis Corporation

RGS

Regis Corporation

N/A

Current Price

$24.26

Market Cap

72.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
VRCA
RGS
Founded
2013
1922
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
88.0M
72.6M
IPO Year
2018
1994

Fundamental Metrics

Financial Performance
Metric
VRCA
RGS
Price
$3.55
$24.26
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $13.83
N/A
AVG Volume (30 Days)
★ 59.0K
13.2K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.18
Revenue
$35,577,000.00
★ $224,485,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$60.79
$1.68
P/E Ratio
★ N/A
$133.72
Revenue Growth
★ 370.22
6.83
52 Week Low
$3.08
$19.31
52 Week High
$9.82
$32.00

Technical Indicators

Market Signals
Indicator
VRCA
RGS
Relative Strength Index (RSI) 47.56 31.19
Support Level $3.30 $24.00
Resistance Level $5.94 $29.05
Average True Range (ATR) 0.30 1.32
MACD 0.04 -0.67
Stochastic Oscillator 45.87 8.26

Price Performance

Historical Comparison
VRCA
RGS

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About RGS Regis Corporation

Regis Corporation franchises, owns, and operates hair care salons, mainly in North America, with licensed locations in the U.K. Its salons provide haircutting, styling, shampooing and conditioning, hair coloring and related services, and also sell hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, Cost Cutters, First Choice Haircutters and Roosters. Its operating segments are Franchise and Company-Owned, with the majority of its revenue generated from the Franchise segment.

Share on Social Networks: